OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
November 30, 2023
Supplemental new drug application for roflumilast cream 0.15% to treat atopic dermatitis in patients 6 years of age and older was assigned a Prescription Drug User Fee Act target action date of July 07, 2024.
November 29, 2023
KarXT (xanomeline-trospium) is currently in development to treat schizophrenia and psychosis related to Alzheimer disease.
Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for patients with severe OSA.
November 28, 2023
The launch of the Elecsys HBeAg quant immunoassay adds to Roche's viral hepatitis testing portfolio.
Ogsiveo is the first and only drug approved by the FDA to treat desmoid tumors.
November 27, 2023
Trial results expected to accelerate the potential of Dupixent to become the first FDA-approved treatment for chronic obstructive pulmonary disease.
AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly), whereas AbbVie will be responsible for further global commercialization.
Manufacturer states that novel drug is the most advanced multi-food oral immunotherapy drug candidate currently in development.
November 22, 2023
Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are.
November 17, 2023
Enzalutamide (Xtandi) from Astellas Pharma Inc. and Pfizer Inc. gets FDA approval to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.